Your browser doesn't support javascript.
loading
Are natural killer cells superior CAR drivers?
Klingemann, Hans.
Afiliación
  • Klingemann H; Tufts University School of Medicine; Boston, MA USA ; Conkwest Inc.; Cambridge, MA USA.
Oncoimmunology ; 3: e28147, 2014.
Article en En | MEDLINE | ID: mdl-25340009
ABSTRACT
T lymphocytes engineered to express a chimeric antigen receptor (CAR) are being celebrated as a major breakthrough of anticancer immunotherapy. Natural killer cells have not received similar attention as CAR effectors, although the use of these relatively short-lived cytotoxic cells is associated with several advantages.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Oncoimmunology Año: 2014 Tipo del documento: Article